Shire, Microsoft and EURORDIS-Rare Diseases Europe announced a strategic alliance to address the diagnostic challenge for patients living with a rare disease.
New data from the VOYAGE 2 club incalculable trial demonstrated high efficacy response rates were achieved with continuous Tremfya (guselkumab) treatment versus withdrawal.
Celgene Corporation announced that data from the phase III RELIEF clinical trial of Oteza (apremilast) in patients with active Behçet’s Disease showed statistically significant reductions in oral ulcers with apremilast 30 mg twice daily versus placebo through week 12.
PANTS study shows that CT-P13 is an efficacious therapy option when investigating personalised approaches to anti-TNF therapy.
The names of the tools may be changing, but the goal for brand managers remains the same in 2018: getting as close as possible to real patients and their needs.
Med Ad News asked its sources what are some of the key industry trends for 2018.
It’s not a new trend. For years, there has been massive speculation on the many ways Amazon could be getting into healthcare. But if you look past the hype, beyond Amazon’s theoretical intentions, and focus more closely on today’s consumer, there is a colossal healthcare trend underway even without Amazon getting in on the game. One can learn a lot from the trend of Amazon’s influence on the business of doing business. So let’s take a closer look …
According to the consultants at PwC, the top health industry issues of 2018 will be …
Deal activity is rampant as Big Pharma gobbles up next-generation medicines and technologies to help overcome maturing pipelines and biosimilar threats.
As more innovative – yet even more expensive – therapies enter the U.S. market, brand marketers will have to find equally new and innovative ways to prove the value of their medicines to payers and patients, especially as insurance plans continue to put more of the cost burden on patients.